Selected Antineoplastic Systemic Enzyme Inhibitors/Strong 3A4 Inducers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may speed up how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your cancer medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. August, 2012.
2.Cometriq (cabozantinib) US prescribing information. Exelixix, Inc. November 29, 2012.
3.Xalkori (crizotinib) US prescribing information. Pfizer Inc. January, 2012.
4.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company October, 2011.
5.Tarceva (erlotinib) US prescribing information. Genentech, Inc. April, 2012.
6.Iressa (gefitinib tablets) US prescribing information. AstraZeneca Pharmaceuticals LP April 7, 2004.
7.Gleevec (imatinib mesylate) US prescribing information. Novartis Pharmaceuticals Corporation February, 2013.
8.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline February, 2012.
9.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation December, 2012.
10.Votrient (pazopanib) US prescribing information. GlaxoSmithKline November, 2012.
11.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation August, 2012.
12.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. November, 2012.
13.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP October, 2012.
14.Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004 Feb;53(2):102-6.
15.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
